Japan Tobacco Inc. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 60
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: J914AEE3103EN
Leaflet:

Download PDF Leaflet

Japan Tobacco Inc. - Product Pipeline Review - Q4 2010
Japan Tobacco Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Japan Tobacco Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Japan Tobacco Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Japan Tobacco Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Japan Tobacco Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Japan Tobacco Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Japan Tobacco Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Japan Tobacco Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Japan Tobacco Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Japan Tobacco Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Japan Tobacco Inc. and identify potential opportunities in those areas.
Japan Tobacco Inc. Snapshot
Japan Tobacco Inc. Overview
Key Information
Key Facts
Japan Tobacco Inc. – Research and Development Overview
Key Therapeutic Areas
Japan Tobacco Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Japan Tobacco Inc. – Pipeline Products Glance
Japan Tobacco Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Japan Tobacco Inc. – Drug Profiles
JTE-607
  Product Description
  Mechanism of Action
  R&D Progress
JTK-003
  Product Description
  Mechanism of Action
  R&D Progress
JTS-653
  Product Description
  Mechanism of Action
  R&D Progress
JTT-130
  Product Description
  Mechanism of Action
  R&D Progress
JTT-302
  Product Description
  Mechanism of Action
  R&D Progress
JTT-552
  Product Description
  Mechanism of Action
  R&D Progress
JTT-705 + Atorvastatin
  Product Description
  Mechanism of Action
  R&D Progress
JTT-705 + Simvastatin
  Product Description
  Mechanism of Action
  R&D Progress
RG1658
  Product Description
  Mechanism of Action
  R&D Progress
Elvitegravir_
  Product Description
  Mechanism of Action
  R&D Progress
JTE-607
  Product Description
  Mechanism of Action
  R&D Progress
JTK-656
  Product Description
  Mechanism of Action
  R&D Progress
JTK-853
  Product Description
  Mechanism of Action
  R&D Progress
JTT-654
  Product Description
  Mechanism of Action
  R&D Progress
Japan Tobacco Inc. – Pipeline Analysis
Japan Tobacco Inc. – Pipeline Products by Therapeutic Class
Japan Tobacco Inc. Pipeline Products By Target
Japan Tobacco Inc. – Pipeline Products by Route of Administration
Japan Tobacco Inc. – Pipeline Products by Molecule Type
Japan Tobacco Inc. – Recent Pipeline Updates
Japan Tobacco Inc. - Dormant Projects
Japan Tobacco Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
JTK-652
JTT-551
JTT-553
JTT-651
Japan Tobacco Inc. – Company Statement
Japan Tobacco Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Japan Tobacco Inc., Deals Volume Summary, 2004 to YTD 2010
Japan Tobacco Inc., Deals Summary By Region, 2004 to YTD 2010
Japan Tobacco Inc., Deals Summary, 2004 to YTD 2010
Japan Tobacco Inc. Detailed Deal Summary
Acquisition
Mitsui Fudosan acquires Frontier REIT Management from Japan Tobacco
Orphagen Pharmaceuticals Enters Into Collaboration Agreement With Japan Tobacco
Arcadia Biosciences Forms Licensing Agreement With Japan Tobacco
Toray Enters Into Co-Development Agreement With Japan Tobacco And Torii Pharmaceutical
Toray Industries Enters Into Agreement With Japan Tobacco
Roche Signs An Agreement With Japan Tobacco
Licensing Agreements
Merck & Co Signs A Licensing Agreement With Japan Tobacco
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Japan Tobacco And Torii Pharmaceutical
MedImmune Enters Into Licensing Agreement With Japan Tobacco
Japan Tobacco Enters Into Licensing Agreement With GlaxoSmithKline
Gilead Sciences Enter Into Licensing Agreement With Japan Tobacco
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 60

LIST OF TABLES

Japan Tobacco Inc. – Pipeline by Therapy Area and Indication, 2010
Japan Tobacco Inc. – Pipeline by Stage of Development, 2010
Japan Tobacco Inc. – Monotherapy Products in Pipeline, 2010
Japan Tobacco Inc. – Combination Treatment Modalities in Pipeline, 2010
Japan Tobacco Inc. - Phase II, 2010
Japan Tobacco Inc. - Phase I, 2010
Japan Tobacco Inc. - Pipeline By Therapeutic Class, 2010
Japan Tobacco Inc. - Pipeline By Target, 2010
Japan Tobacco Inc. – Pipeline By Route of Administration, 2010
Japan Tobacco Inc. – Pipeline By Molecule Type, 2010
Japan Tobacco Inc. – Recent Pipeline Updates, 2010
Japan Tobacco Inc. - Dormant Developmental Projects, 2010
Japan Tobacco Inc. - Discontinued Pipeline Products, 2010
Japan Tobacco Inc., Subsidiaries
Japan Tobacco Inc., Deals Summary, 2004 to YTD 2010
Japan Tobacco Inc., Deals Summary by Region, 2004 to YTD 2010
Japan Tobacco Inc., Deals Summary, 2004 to YTD 2010
Mitsui Fudosan acquires Frontier REIT Management from Japan Tobacco
Orphagen Pharmaceuticals Enters Into Collaboration Agreement With Japan Tobacco
Arcadia Biosciences Forms Licensing Agreement With Japan Tobacco
Toray Enters Into Co-Development Agreement With Japan Tobacco And Torii Pharmaceutical
Toray Industries Enters Into Agreement With Japan Tobacco
Roche Signs An Agreement With Japan Tobacco
Merck & Co Signs A Licensing Agreement With Japan Tobacco
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Japan Tobacco And Torii Pharmaceutical
MedImmune Enters Into Licensing Agreement With Japan Tobacco
Japan Tobacco Enters Into Licensing Agreement With GlaxoSmithKline
Gilead Sciences Enter Into Licensing Agreement With Japan Tobacco 58

LIST OF FIGURES

Japan Tobacco Inc. – Pipeline by Therapy Area and Indication, 2010
Japan Tobacco Inc. – Pipeline by Stage of Development, 2010
Japan Tobacco Inc. – Monotherapy Products in Pipeline, 2010
Japan Tobacco Inc. – Combination Treatment Modalities in Pipeline, 2010
Japan Tobacco Inc. – Pipeline By Therapeutic Class, 2010
Japan Tobacco Inc. - Pipeline By Target, 2010
Japan Tobacco Inc. – Pipeline By Route of Administration, 2010
Japan Tobacco Inc. – Pipeline By Molecule Type, 2010 36

Ask Your Question

Japan Tobacco Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: